Close Menu

NEW YORK – Quest Diagnostics on Thursday raised its full-year 2020 guidance saying it now expected revenues of between $8.4 billion and $8.8 billion compared to a previous guidance of $8 billion to $8.6 billion.

The average Wall Street estimate is $8.7 billion.

In a statement, the company said that since it reported its Q2 2020 financial results, organic testing volumes for its base business have recovered faster than expected. Test volumes were down in the high single digits in July and in the mid-to-high single digits in August compared to the prior year.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.